NeuroRx, Inc. is developing NRX-101, the first oral therapeutic for the treatment of Acute Suicidal Ideation and Behavior (ASIB) in Bipolar Depression (ASIB). Currently, there is no approved drug for patients with suicidal depression and current SSRI antidepressants bear an FDA warning about possible increased risk of suicide, leaving hospitalization and electroshock therapy as the only accepted treatment. The company is built upon 30 years of basic science and clinical expertise in understanding the role of the brain’s NMDA receptor in regulating human thought processes, particularly depression and suicidality. NeuroRx is currently initiating its Phase 2b/3 clinical trial of NRX-101.
